Skip to main content

Table 6 The characteristics of patients after 10 weeks follow-up

From: Amphotericin B plus fluorocytosine combined with voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study

Variables

Group I (n = 15)

Group II(n = 30)

Group III(n = 18)

P-value

BMRC stage (n, %)

0.620

 1

9(60.0%)

14(46.7%)

12(66.7%)

 2

6(40.0%)

14(46.7%)

6(33.3%)

 3

0(0%)

2(6.7%)

0(0%)

Number of lumbar punctures within 10 weeks, median (IQR)

6(4–10)

7(6–11.25)

7(6–8.25)

0.143

CSF opening pressure, median (IQR), mmH2O

140(115–220)

175(128.75–232.5)

179(135–207.5)

0.437

CSF cryptococci, median (IQR), count/ml

0(0–0)

0(0–0.75)

0(0–3)

0.868

CSF clearance

Case (n, %)

11(73.3%)

22(73.3%)

13(72.2%)

1.000

 CSF white blood cell, median (IQR), *10^6/l

8(3–22)

16(8–48)

19(7.5–36.5)

0.163

 CSF protein, median (IQR), g/l

0.42(0.29–0.75)

0.62(0.36–1.31)

0.57(0.35–1.40)

0.310

 CSF glucose, median (IQR), g/l

2.63(2.18–3.90)

2.45(2.11–2.85)

2.64(2.07–3.09)

0.627

 CSF chloride, median (IQR), mmol/l

122.2(120.4–125)

121.5(117.48–125)

122.45(121.4–126.03)

0.407

Treatment Outcomes (n, %)

 Complete response

8(53.3%)

14(46.7%)

11(61.1%)

0.622

 Partial response

3(20.0%)

6(20.0%)

2(11.1%)

0.757

 Stable response

4(26.7%)

8(26.7%)

5(27.8%)

0.709

 Disease progression

0(0%)

1(3.3%)

0(0%)

1.000

 Death

0(0%)

1(3.3%)

0(0%)

1.000

Adverse events (n, %)

15(100%)

30(100%)

18(100%)

NA

Chills and fevers

0(3.4%)

2(6.7%)

2(11.1%)

0.565

Hypokalemia

7(46.7%)

27(90.0%)

17(94.4%)

0.001*

Mild hypokalemia

0(0%)

6(20.0%)

3(16.7%)

0.188

Moderate hypokalemia

6(40.0%)

13(43.3%)

11(61.1%)

0.388

Severe hypokalemia

1(6.7%)

8(26.7%)

3(16.7%)

0.317

Gastrointestinal discomfort

1(6.7%)

15(50.0%)

4(22.2%)

0.008*

Liver impairment

6(40.0%)

22(73.3%)

12(66.7%)

0.088

Renal impairment

11(73.3%)

19(63.3%)

7(38.9%)

0.105

Mild renal impairment

6(40.0%)

8(26.7%)

3(16.7%)

0.308

Moderate renal impairment

4(26.7%)

9(30.0%)

2(11.1%)

0.346

Severe renal impairment

1(6.7%)

2(6.7%)

2(11.1%)

0.844

Anemia

4(26.7%)

12(40.0%)

7(38.9%)

0.661

Phlebitis

1(6.7%)

2(6.7%)

1(5.6%)

1.000

Visual side effects

1(6.7%)

0(0%)

0(0%)

0.238

  1. Group I: AMB + 5-FC + VOR, Group II: AMB + 5-FC + FLU, Group III: AMB + 5-FC. Data were presented as median (IQR). Continuous variables were analyzed by one-way ANOVA or Kruskal–Wallis H test. Categorical variables were analyzed by Chi-square test or Fisher’s exact test. *P < 0.05. Note: there were 6 observed deaths by week 10 of follow-up. 1 patient died at 3rd week of follow-up, 1 patient died at 5th week of follow-up, 2 patients died at 7th week of follow-up, 1 patient died at 8th week of follow-up and 1 patient died at 10th week of follow-up. The 5 patients who died after less than 10 weeks of follow-up were not analyzed at 10 weeks of follow-up. The 10-week mortality in our study was 6/148 (4.1%)